JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Eli Lilly and Co.

Gesloten

SectorGezondheidszorg

765.52 -0.26

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

759.46

Max

769.31

Belangrijke statistieken

By Trading Economics

Inkomsten

-6.1B

2.8B

Verkoop

-804M

13B

K/W

Sectorgemiddelde

66.239

40.048

Dividendrendement

0.66

Winstmarge

21.678

Werknemers

47,000

EBITDA

-2B

4.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+33.78% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.66%

2.45%

Volgende Winsten

7 aug 2025

Volgende dividenddatum

10 sep 2025

Volgende Ex Dividend datum

15 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-98B

730B

Vorige openingsprijs

765.78

Vorige sluitingsprijs

765.52

Nieuwssentiment

By Acuity

60%

40%

331 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Eli Lilly and Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 jun 2025, 11:56 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27 mei 2025, 14:41 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

30 jul 2025, 10:38 UTC

Marktinformatie

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

29 jul 2025, 17:05 UTC

Winsten

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29 jul 2025, 16:55 UTC

Winsten

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29 jul 2025, 13:35 UTC

Winsten

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

29 jul 2025, 11:39 UTC

Winsten

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

25 jul 2025, 12:49 UTC

Acquisities, Fusies, Overnames

Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

24 jul 2025, 12:02 UTC

Acquisities, Fusies, Overnames

Eli Lilly Expects to Complete Verve Acquisition on July 25 >LLY VERV

24 jul 2025, 12:01 UTC

Acquisities, Fusies, Overnames

Eli Lilly: About 55.7% of Verve Shares Tendered >LLY VERV

24 jul 2025, 12:00 UTC

Acquisities, Fusies, Overnames

Lilly and Verve Announce Expiration of Verve Tender Offer

9 jul 2025, 09:17 UTC

Populaire aandelen

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

17 jun 2025, 14:02 UTC

Acquisities, Fusies, Overnames

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 jun 2025, 12:12 UTC

Acquisities, Fusies, Overnames

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 jun 2025, 11:01 UTC

Acquisities, Fusies, Overnames

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 jun 2025, 10:47 UTC

Acquisities, Fusies, Overnames

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 jun 2025, 10:47 UTC

Acquisities, Fusies, Overnames

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 jun 2025, 10:46 UTC

Acquisities, Fusies, Overnames

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 jun 2025, 10:45 UTC

Acquisities, Fusies, Overnames

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 jun 2025, 09:33 UTC

Acquisities, Fusies, Overnames

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11 jun 2025, 09:45 UTC

Marktinformatie

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29 mei 2025, 01:00 UTC

Top Nieuws

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New -2-

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 mei 2025, 14:02 UTC

Acquisities, Fusies, Overnames

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 mei 2025, 14:01 UTC

Acquisities, Fusies, Overnames

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 mei 2025, 14:00 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 mei 2025, 14:00 UTC

Acquisities, Fusies, Overnames

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 mei 2025, 14:08 UTC

Winsten

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 mei 2025, 22:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

Peer Vergelijking

Prijswijziging

Eli Lilly and Co. Prognose

Koersdoel

By TipRanks

33.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,028.8 USD  33.78%

Hoogste 1,190 USD

Laagste 883 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Eli Lilly and Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

17

Buy

2

Hold

0

Sell

Technische score

By Trading Central

N/A / 884.54Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

331 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.